BioSpace News Archive

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting virtually on Wednesday, August 12, 2020 at 9 a.m. ET in Track 5 at the Canaccord Genuity 40th Annual Growth Conference.

RespireRx Pharmaceuticals Inc., is pleased to announce that , Mr. Tim Jones and RespireRx have transitioned from the provisional period that commenced on May 6, 2020 to the three year, long-term portion of the employment contract with Mr. Jones as its President and Chief Executive Officer.

Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced a collaboration with Hospital for Special Surgery in New York City.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of NeXT Liquid Biopsy, a high-performance, exome-scale, tumor-profiling platform that utilizes blood samples from advanced-stage solid tumor cancer patients. NeXT Liquid Biopsy, paired with Personalis’ leading ImmunoID NeXT™ tissue profiling platform, enables a more comprehensive immuno-genomics view of the tumor that

Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the appointment of Denis Drygin , Ph.D., as Chief Scientific Officer effective August 3 , 2020.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2020 financial results prior to market open on Monday, August 10, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. The confer

- Novel Chromatinase™ platform could rapidly and systemically removes NETs associated with exacerbation of COVID-19 - Investigational biologic aims to treat hyperinflammation and thrombosis in COVID-19 patients, including those with Acute Respiratory Distress Syndrome (ARDS) - Neutrolis awarded competitive grant from the National Institutes of Health (NIH) - Recent study published in The Lancet EBioMedicine found NETs in COVID-19 patients

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 10, 2020 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (I

MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy (HCM) who have been referred for septal reduction therapy (SRT) and are refractory to current therapeutic options, including those who have severe symptoms (NYHA Class IV). VALOR-HCM is designed to provide direct clinical evidence of mavacamten’

miR Scientific LLC, a precision biosciences company committed to transforming cancer management announced that it has been selected as a finalist in the Fierce Innovation Awards – Life Sciences Edition 2020, a peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma.